Astrazeneca (AZN) Cost of Revenue (2016 - 2026)

Astrazeneca has reported Cost of Revenue over the past 16 years, most recently at $2.7 billion for Q1 2026.

For Q1 2026, Cost of Revenue rose 19.5% year-over-year to $2.7 billion; the TTM value through Mar 2026 reached $11.1 billion, up 8.21%, while the annual FY2025 figure was $10.6 billion, 4.17% up from the prior year.
Cost of Revenue for Q1 2026 was $2.7 billion at Astrazeneca, down from $3.1 billion in the prior quarter.
Over five years, Cost of Revenue peaked at $3.5 billion in Q1 2022 and troughed at $1.9 billion in Q1 2023.
A 5-year average of $2.6 billion and a median of $2.7 billion in 2026 define the central range for Cost of Revenue.
Biggest five-year swings in Cost of Revenue: surged 138.4% in 2022 and later tumbled 45.74% in 2023.
Year by year, Cost of Revenue stood at $2.9 billion in 2022, then fell by 20.41% to $2.3 billion in 2023, then grew by 18.07% to $2.7 billion in 2024, then grew by 14.42% to $3.1 billion in 2025, then dropped by 14.11% to $2.7 billion in 2026.
Business Quant data shows Cost of Revenue for AZN at $2.7 billion in Q1 2026, $3.1 billion in Q4 2025, and $2.8 billion in Q3 2025.

Peer Comparison